Latest filing published 27 Aug 2021 for Scopus BioPharma Inc., €834.
Filing timeline
BuySaleInsider track record
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Joshua R. Lamstein: trading record in brief
Joshua R. Lamstein is a declared insider at 2 companies (chief executive); the most frequent names are Scopus BioPharma Inc. and PAVmed Inc. We count 10 filings; the first trade dates from 18 November 2016 and the latest from 27 August 2021.
Purchases make up the whole of the open-market record (9 purchases, €22k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2021, the count stands at 7 purchases and no sales.
The median purchase comes to €1,083. Of 5 purchases, 5 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
On 27 August 2021 came the latest disclosure, an open-market purchase for €851 in Scopus BioPharma Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Joshua R. Lamstein
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 200 shares@ US$4.908.7% of flowCommon Stock, par value $0.001SEC:0001104659-21-110652:0Canonical exit: 24 Nov 2021 (T+90)
- 800 shares@ US$4.0428.8% of flowCommon Stock, par value $0.001SEC:0001104659-21-108657:0Canonical exit: 17 Nov 2021 (T+90)
- 1,500 shares@ US$4.7162.5% of flowCommon Stock, par value $0.001SEC:0001104659-21-096342:0Canonical exit: 21 Oct 2021 (T+90)
3 of 3 declarations